# Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)

> **NCT00392678** · PHASE2,PHASE3 · COMPLETED · sponsor: **Joslin Diabetes Center** · enrollment: 277 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Salsalate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00392678
- **Lead sponsor:** Joslin Diabetes Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-07
- **Final completion:** 2010-12
- **Target enrollment:** 277 (ACTUAL)
- **Last updated:** 2019-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00392678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00392678, "Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00392678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*